Fernández-Castañer M - Search Results

1

Beta-cell dysfunction in first-degree relatives of patients with non-insulin-dependent diabetes mellitus.

Fernández-Castañer M, Biarnés J, Camps I, Ripollés J, Gómez N, Soler J. Fernández-Castañer M, et al. Diabet Med. 1996 Nov;13(11):953-9. doi: 10.1002/(SICI)1096-9136(199611)13:11<953::AID-DIA257>3.0.CO;2-V. Diabet Med. 1996. PMID: 8946153

2

Age, sex and ICA influence on beta-cell secretion during the first year after the diagnosis of type 1 diabetes mellitus.

Montaña E, Fernandez-Castañer M, Rosel P, Gomez J, Soler J. Montaña E, et al. Diabete Metab. 1991 Sep-Oct;17(5):460-8. Diabete Metab. 1991. PMID: 1752347

3

Increased prothrombin fragment 1 + 2 and D-dimer in first-degree relatives of type 2 diabetic patients. Prethrombotic state in relatives of type 2 diabetic patients.

Fernández-Castañer M, Camps I, Fernández-Real JM, Domenech P, Martínez-Brotons F. Fernández-Castañer M, et al. Acta Diabetol. 1996 Jul;33(2):118-21. doi: 10.1007/BF00569421. Acta Diabetol. 1996. PMID: 8870813

4

Ketoacidosis at diagnosis is predictive of lower residual beta-cell function and poor metabolic control in type 1 diabetes.

Fernandez Castañer M, Montaña E, Camps I, Biarnes J, Merino JF, Escriba JM, Nacher V, Rosel P, Soler J. Fernandez Castañer M, et al. Diabetes Metab. 1996 Oct;22(5):349-55. Diabetes Metab. 1996. PMID: 8896997

5

Improved metabolic control preserved beta-cell function two years after diagnosis of insulin-dependent diabetes mellitus.

Montanya E, Fernandez-Castañer M, Soler J. Montanya E, et al. Diabetes Metab. 1997 Sep;23(4):314-9. Diabetes Metab. 1997. PMID: 9342545 Clinical Trial.

6

Differential regulation of insulin action and tumor necrosis factor alpha system activity by metformin.

Biarnés J, Fernández-Real JM, Fernández-Castañer M, del Mar García M, Soler J, Ricart W. Biarnés J, et al. Among authors: fernandez castaner m. Metabolism. 2005 Feb;54(2):235-9. doi: 10.1016/j.metabol.2004.08.018. Metabolism. 2005. PMID: 15690319 Clinical Trial.

7

The influence of insulin antibodies on metabolic deterioration after interruption of continuous subcutaneous insulin infusion.

Montaña E, Fernández-Castañer M, Rosel P, Gómez JM, Vinzia C, Soler J. Montaña E, et al. Diabete Metab. 1990 May-Jun;16(3):220-5. Diabete Metab. 1990. PMID: 2210017

8

Lack of relationship between insulin antibodies, metabolic control and insulin requirements in type 1 diabetes.

Fernández Castañer M, Pérez M, Maravall J, Montaña E, Soler J. Fernández Castañer M, et al. Diabet Med. 1996 Jul;13(7):686-7. doi: 10.1002/(SICI)1096-9136(199607)13:7<686::AID-DIA155>3.0.CO;2-P. Diabet Med. 1996. PMID: 8840111 No abstract available.

9

[The influence of clinical presentation and metabolic control of insulin dependent diabetes in the evolution of residual insulin secretion. A prospective study at five years].

Fernández Castañer M, Gonzálbez J, Carrera MJ, Nacher V, Montanya E, Abós R, Soler J. Fernández Castañer M, et al. Med Clin (Barc). 1997 Sep 20;109(9):328-32. Med Clin (Barc). 1997. PMID: 9379763 Spanish.

10

Clinical presentation and early course of type 1 diabetes in patients with and without thyroid autoimmunity.

Fernández-Castañer M, Molina A, López-Jiménez L, Gómez JM, Soler J. Fernández-Castañer M, et al. Diabetes Care. 1999 Mar;22(3):377-81. doi: 10.2337/diacare.22.3.377. Diabetes Care. 1999. PMID: 10097913

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

41 results

Search Page

Filters